mastodon.ie is one of the many independent Mastodon servers you can use to participate in the fediverse.
Irish Mastodon - run from Ireland, we welcome all who respect the community rules and members.

Administered by:

Server stats:

1.8K
active users

#geriatrics

2 posts2 participants0 posts today

If only this could have been predicted!
People age so irregularly.

America's aging population faces a growing shortage of geriatric care

"More than 80 million Americans are expected to be older than 65 by 2050,"

"only 174 out of 419 available positions in geriatric specialty programs were filled in 2023, making it one of the most unfilled programs the organization tracks."

#aging #geriatrics #healthcare

businessinsider.com/geriatric-

Me w/Dr. Matthew Lefferman, a kind dr. He specializes in #geriatrics & goes to the places where his expertise is needed. Here we are @ the Kensington Redondo (he's holding my book, Finding the Right Words: A Story of Literature, Grief, and the Brain), where we watched "Taking Care," a beautiful film honoring Adele Miller, mother to Lauren Miller Rogen & mother-in-law to Seth Rogen. Their foundation, HFC, supports #caregivers of people with #dementia.

#EndAlz
#LaurenMillerRogen
#SethRogen

As I handle all my MIL's financial & legal and admin stuff, I'm on her retirement community email list. There's a notable uptick of "in memory" emails this past month. I've not been tracking the data, but it feels like it's almost daily & more than before. Wonder why. I know of course about big spread of flu, RSV, Covid, etc. this winter. Or perhaps there's uptick in geriatric deaths each winter normally? This is my first winter on the mailing list. #Health #Geriatrics #ActuarialTables #Covid

🥳 Huge congratulations to Estelle Tran Van Hoi for pulling of this impressive paper

📔 Blood based immune #biomarkers associated with clinical #frailty scale in older patients with melanoma receiving checkpoint inhibitor #immunotherapy

❓What is association with outcomes?

🔗 doi.org/10.1186/s12979-024-004

BioMed CentralBlood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy - Immunity & AgeingIntroduction Immunotherapy with checkpoint inhibition (ICI) is increasingly prescribed to older patients with cancer. High age, especially in combination with frailty, has been associated to immune senescence, which is the age-related decline in immune function, thereby possibly hindering ICI effectiveness. This cross-sectional study aimed to assess whether blood cell immune senescence markers are associated with age, frailty and response to anti-PD-1 treatment in older patients with metastatic melanoma. Methods In a prospective observational study, sixty patients with stage IIIC or IV melanoma undergoing anti-PD1 treatment were categorized into young (< 65 years; n = 22), old (> 65 years) without frailty (n = 19), and old with frailty (n = 19). In-depth immune cell phenotyping was performed in baseline blood samples (prior to treatment) using multispectral flow cytometry and compared between groups and with immunotherapy treatment response. Antigen-presenting cell capacity was evaluated using mixed lymphocyte reaction and T cell proliferative potential was assessed using PHA proliferation assay. Results No significant differences in treatment response rates were observed across age groups. Older patients, irrespective of frailty, showed lower levels of naïve CD8 + T cells, with the old and frail group also exhibiting reduced tissue-resident effector memory CD8 + T cells and CD8 + mucosal associated invariant T (MAIT) cells. These differences were not associated with treatment outcomes. T cell proliferation and antigen-presenting cell capacities did not differ across groups. Conclusion Several ageing and frailty associated changes were detected among circulating immune cells in blood but were not associated with response to immunotherapy in our study. While these findings suggest that the level of frailty and ageing may not necessarily preclude the efficacy of ICI therapy, further investigation is needed to fully understand the impact of frailty and ageing on immunotherapy.